Alzamend Neuro is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases and psychiatric disorders, specifically targeting conditions such as Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder (PTSD). The company’s primary focus is on two therapeutic drug candidates: AL001 and ALZN002. AL001 utilizes a patented ionic cocrystal technology that combines lithium, proline, and salicylate to create a novel lithium-delivery system. This formulation aims to provide the therapeutic benefits of lithium while minimizing the associated toxicities, making it a potentially safer alternative for patients suffering from dementia related to Alzheimer’s.

In addition to AL001, Alzamend Neuro is developing ALZN002, which employs a mutant-peptide sensitized cell as a therapeutic vaccine designed to enhance the immune system's ability to combat Alzheimer’s disease. Both candidates are licensed from the University of South Florida Research Foundation, Inc., under exclusive worldwide licenses. The company is committed to advancing these therapies through clinical trials, with AL001 already demonstrating promising results in early-phase studies, indicating its potential to deliver effective treatment options for millions of individuals affected by these debilitating conditions.

United States

Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company’s lead product candidate is AL001 for the treatment of Alzheimer’s and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient’s immunological system to Alzheimer’s. The company was incorporated in 2016 and is headquartered in Tampa, Florida.

Central Nervous System (CNS)

Nervous System Diseases

Psychological Diseases

Alzamend Neuro 

Bipolar disease

AL001 is a patented ionic cocrystal technology delivering lithium via a &nbsp;therapeutic crystal-engineered combination of lithium, proline and &nbsp;salicylate, known as AL001 or LiProSal, through two royalty-bearing &nbsp;exclusive worldwide licenses from the University of South Florida &nbsp;Research Foundation, Inc.

AL001

Alzheimer's disease

AL001 

Major depressive disorder

AL001  

Post-traumatic stress disorder

AL001   

Dementia

ALZN002, is a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine which seeks to restore the ability of the patient’s immunological system to combat Alzheimer’s. The proposed mechanism of action of ALZN002 is through the pulsed-Dendritic Cell (“DC”) activation of T-cells that stimulates the immune system, resulting in the clearance of brain amyloid.
 
ALZN002 is based on the theory that Alzheimer’s symptoms may be caused in large part by plaque deposits that can cluster in the brain composed of protein fragments called beta-amyloids that build up between nerve cells. One hypothesis is that a special type of immune cell, natural beta-amyloid antibodies, may play a role in preventing plaque build-up in people without Alzheimer’s. As people age, their immune systems may degrade, and some people may be unable to produce natural beta-amyloid antibodies, the absence of which leads to the plaque build-up causing Alzheimer’s. ALZN002 is intended to elicit an immune response to produce anti-amyloid antibodies, which can then neutralize circulated beta-amyloids and prevent additional plaque build-up. The mutant antigen within ALZN002 was selected specifically for its high HLA binding affinity, thereby avoiding the need for an adjuvant, which may cause an adverse (Th1) immune response. ALZN002 is an autologous modified DC treatment. More precisely, it is a patient-specific therapy where the patient undergoes leukapheresis, a nonsurgical treatment used to reduce the quantity of white blood cells in the bloodstream, to isolate peripheral blood monocytes that are subsequently matured into DCs using an IL4+ GM-CSF cocktail. The DCs are incubated with a modified amyloid beta (Aβ) peptide (“ALZN002 peptide”) to sensitize them, and then administered to the same patient.

Alzamend Neuro

Company Details